| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| equivalentClass
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Organic Chemical
- Pharmacologic Substance
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - (Oral) Acute promyelocytic leukemia (APL), characterized by the t(15;17) translocation or the PML/RARa gene refractory to or have relapsed from anthracycline chemotherapy, or for where anthracycline-based chemotherapy is contraindicated
- (Topical) acne vulgaris; other dermatologic conditions; some skin cancers
|
| In_Clinical_Trial_For
| - Acute promyelocytic leukemia; acute myeloid leukemia; high risk myelodysplastic syndrome; neuroblastoma
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-SYDTPNSC0122758
- trans-Retinoic acidSYDTPNSC0122758
- TretinoinumSYNCI
- TretinoinPTDCP00404
- All-trans Retinoic AcidSYNCI
- ATRAPTNCI-GLOSSCDR0000467823
- AirolSYDTPNSC0122758
- Retin-A MICROBRNCI
- All-trans Vitamin A AcidSYNCI
- Retinoic AcidSYNCI
- Vitamin A AcidSYNCI
- Stieva-A ForteFBNCI
- AberelSYDTPNSC0122758
- EudynaSYDTPNSC0122758
- Vitamin A acidSYDTPNSC0122758
- AvitaPTNCI-GLOSSCDR0000410738
- Retin-ASYDTPNSC0122758
- Retin-A-MicroPTNCI-GLOSSCDR0000467822
- ATRAABNCI
- AknotenSYDTPNSC0122758
- retinoic acidPTNCI-GLOSSCDR0000467821
- RenovaPTNCI-GLOSSCDR0000410739
- AirolFBNCI
- AvitaBRNCI
- vitamin A acidPTNCI-GLOSSCDR0000467820
- Retin-APTNCI-GLOSSCDR0000410740
- all trans-Retinoic acidSYDTPNSC0122758
- all-trans-Retinoic acidSYDTPNSC0122758
- TRETINOINPTFDA5688UTC01R
- AberelBRNCI
- EudynaFBNCI
- RenovaBRNCI
- beta-Retinoic AcidSYNCI
- Ro 5488CNNCI
- Retin-ABRNCI
- (All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic AcidSNNCI
- AknotenBRNCI
- DermairolSYDTPNSC0122758
- all-trans-Vitamin A acidSYDTPNSC0122758
- Trans Retinoic AcidSYNCI
- trans-Retinoic AcidSYNCI
- VesanoidPTNCI-GLOSSCDR0000467819
- Stieva-AFBNCI
- VesanoidBRNCI
- VitinoinFBNCI
- Trans Vitamin A AcidSYNCI
- Retisol-AFBNCI
- DermairolFBNCI
- TretinoinPTNCI
- all-trans retinoic acidPTNCI-GLOSSCDR0000367465
- tretinoinPTNCI-GLOSSCDR0000045351
- TretinoinSYNCITCGA
- Epi-AberelFBNCI
- Vitamin A acid, all-trans-SYDTPNSC0122758
- Cordes VasFBNCI
|
| DEFINITION
| - A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties.NCI
|
| code
| |
| sameAs
| |
| http://linked.open...y/mesh/hasConcept
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)